. . "5"^^ . "Antidepressants such as the selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) are commonly used drugs in the treatment of depression. Their use is limited by adverse effects - physical (e.g. akathisia, nausea, diarrhea, sexual dysfunction) and emotional (emotional flattenig, anhedonia). While emotional side effects may be confounded by the residual effects of depression, patients often attribute them to their medication. Emotional side effects have a negative impact on quality of life in remission. Clinicians should ask routinely about emotional side effects when they are assessing treatment with antidepressants. Dopaminergic a norepinehrine antidepressants such as agomelatine, bupropione or reboxetine are drug of choice for patiens suffering from anhedonia and emotional flattening."@en . . "1212-0383" . "CZ - \u010Cesk\u00E1 republika" . "[20FE180D5638]" . . . . "72695" . . "109" . "RIV/00216208:11150/13:10144009" . . . "Antidepresiva skupiny SSRI (selektivn\u00ED inhibitory zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu) a SNRI (inhibitory zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu a noradrenalinu) jsou \u010Dasto u\u017E\u00EDvan\u00FDmi l\u00E9ky p\u0159i l\u00E9\u010Db\u011B deprese. Jejich u\u017Eit\u00ED je omezeno v\u00FDskytem somatick\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F (nap\u0159. akatizie, nausea, pr\u016Fjem, sexu\u00E1ln\u00ED dysfunkce) a paradoxn\u011B i emo\u010Dn\u00EDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F (emo\u010Dn\u00ED opo\u0161t\u011Blost, anhedonie, podr\u00E1\u017Ed\u011Bnost). Emo\u010Dn\u00ED ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky mohou b\u00FDt obt\u00ED\u017En\u011B odli\u0161iteln\u00E9 od rezidu\u00E1ln\u00EDch p\u0159\u00EDznak\u016F deprese. Pacienti v\u0161ak mnohdy tyto p\u0159\u00EDznaky jako obt\u00ED\u017Ee vyvolan\u00E9 pod\u00E1van\u00FDmi antidepresivy rozpozn\u00E1vaj\u00ED. Emo\u010Dn\u00ED ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky maj\u00ED negativn\u00ED vliv na kvalitu \u017Eivota v remisi. L\u00E9ka\u0159i by se m\u011Bli, p\u0159i hodnocen\u00ED l\u00E9\u010Dby antidepresivy, nemocn\u00FDch aktivn\u011B dotazovat na jejich p\u0159\u00EDtomnost. L\u00E9kem volby p\u0159i anhedonii a emo\u010Dn\u00EDm oplo\u0161t\u011Bn\u00ED jsou antidepresiva s dopaminergn\u00EDm a noradrenergn\u00EDm \u00FA\u010Dinkem - agomelatin, bupropionem nebo reboxetin." . . "Emotional flattening and anhedonia in depressive disorder"@en . "11150" . "Emo\u010Dn\u00ED oplo\u0161t\u011Blost a anhedonie u depresivn\u00ED poruchy" . "http://www.cspsychiatr.cz/dwnld/CSP_2013_5_227_231.pdf" . "\u010Cesk\u00E1 a slovensk\u00E1 psychiatrie" . "antidepressants; emotional flattening; anhedonia; agomelatine"@en . "1"^^ . "1"^^ . "Emo\u010Dn\u00ED oplo\u0161t\u011Blost a anhedonie u depresivn\u00ED poruchy"@cs . "Emotional flattening and anhedonia in depressive disorder"@en . . "RIV/00216208:11150/13:10144009!RIV14-MSM-11150___" . . . "Emo\u010Dn\u00ED oplo\u0161t\u011Blost a anhedonie u depresivn\u00ED poruchy" . "5" . "I" . "Antidepresiva skupiny SSRI (selektivn\u00ED inhibitory zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu) a SNRI (inhibitory zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu a noradrenalinu) jsou \u010Dasto u\u017E\u00EDvan\u00FDmi l\u00E9ky p\u0159i l\u00E9\u010Db\u011B deprese. Jejich u\u017Eit\u00ED je omezeno v\u00FDskytem somatick\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F (nap\u0159. akatizie, nausea, pr\u016Fjem, sexu\u00E1ln\u00ED dysfunkce) a paradoxn\u011B i emo\u010Dn\u00EDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F (emo\u010Dn\u00ED opo\u0161t\u011Blost, anhedonie, podr\u00E1\u017Ed\u011Bnost). Emo\u010Dn\u00ED ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky mohou b\u00FDt obt\u00ED\u017En\u011B odli\u0161iteln\u00E9 od rezidu\u00E1ln\u00EDch p\u0159\u00EDznak\u016F deprese. Pacienti v\u0161ak mnohdy tyto p\u0159\u00EDznaky jako obt\u00ED\u017Ee vyvolan\u00E9 pod\u00E1van\u00FDmi antidepresivy rozpozn\u00E1vaj\u00ED. Emo\u010Dn\u00ED ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky maj\u00ED negativn\u00ED vliv na kvalitu \u017Eivota v remisi. L\u00E9ka\u0159i by se m\u011Bli, p\u0159i hodnocen\u00ED l\u00E9\u010Dby antidepresivy, nemocn\u00FDch aktivn\u011B dotazovat na jejich p\u0159\u00EDtomnost. L\u00E9kem volby p\u0159i anhedonii a emo\u010Dn\u00EDm oplo\u0161t\u011Bn\u00ED jsou antidepresiva s dopaminergn\u00EDm a noradrenergn\u00EDm \u00FA\u010Dinkem - agomelatin, bupropionem nebo reboxetin."@cs . . . . "Emo\u010Dn\u00ED oplo\u0161t\u011Blost a anhedonie u depresivn\u00ED poruchy"@cs . "T\u016Fma, Ivan" .